1249-P: How Can Serum Adiponectin Levels Be Evaluated in Clinical Settings?

Abstract

Objective: Adiponectin, an adipocytokine, effects on various metabolic process including glucose regulation, and its decreased levels in serum have been reported as a risk for incident diabetes (DM) . However, cross-sectional studies often reported serum adiponectin levels (Ap) as increased in DM. We hypothesized that such inconsistency can be explained as abnormalities other than DM per se resided in the study subjects to be responsible for the increased Ap. Therefore, we here examined the effects of various conditions such as age, hypertension, dyslipidemia, and factors representing microangiopathies on association between DM and Ap in a general population. Research Design and Methods: Among 1816 participants of the population-based Iwaki study of Japanese held in 2014-2017, 1771 subjects with complete data set including Ap were included, and the association between Ap and the above factors was analyzed by regression analysis and ANOVA with multiple factors adjustment. Results: Ap showed positive correlation (p < 0.each) with age, HDL-cholesterol, and urinary albumin excretion (uACR) , and negative correlation (p < 0.each) with neutral fat, BMI, HbA1c, and waist circumference. As a whole, DM group had lower Ap than non-DM group (p < 0.01) . However, when the subjects were stratified based on uACR (<30 (normal) and >30 mg/gCr) , DM group had significantly lower Ap than non-DM group (p<0.01) in the normal group, but not in the other group (p=0.55) , indicated that increased uACR may be responsible for the increase in Ap in DM. Conclusion: We here showed uACR, an indicator of microangiopathy, as a factor linking such inconsistency. Namely, although Ap is decreased in subjects prone to be diabetic and, thus, patients with DM should have lower Ap accordingly, patients with DM may have increased Ap depending on status of their complication such as microangiopathy. To strengthen this hypothesis, we now conducting analyses with stratification based on various other conditions and, longitudinal analyses as well. Disclosure S.Ono: None. M.Daimon: None. A.Kamba: None. S.Mizushiri: None. M.Murabayashi: None. Y.Nishiya: None. R.Ito: None. A.Tamura: None.